Literature DB >> 18496209

-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population.

Amalia Lafuente1, Miquel Bernardo, Sergi Mas, Anna Crescenti, Monica Aparici, Patricia Gassó, Javier Goti, Vanessa Sanchez, Rosa Catalan, Xavier Carne.   

Abstract

OBJECTIVE: In this study we examined the relationship between dopamine D2 receptor (DRD2) polymorphisms (TaqIA, TaqIB, -141C Ins/Del) and dopamine D3 receptor (DRD3) Ser9Gly polymorphism and the risk of schizophrenia in a Spanish population.
METHODS: Two hundred and forty-three schizophrenia patients and 291 healthy controls from the general population participated in a case-control study.
RESULTS: No significant differences were observed in the allele or genotype frequencies of TaqIA, TaqIB or Ser9Gly polymorphisms between the schizophrenia patients and the healthy controls. The frequency of the -141C Del allele was significantly lower in the former group (odds ratio=0.4, P=0.01). The -141C Del allele, which produces lower expression of DRD2, may protect against dopaminergic hyperactivity in schizophrenia.
CONCLUSION: This study is one of the few studies of Caucasian participants that supports the results obtained in the original Japanese study, in which the -141C Ins/Del polymorphism was first described. Furthermore, our findings reinforce the hypothesis that excess dopaminergic activity leads to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496209     DOI: 10.1097/YPG.0b013e3282fb0019

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  7 in total

1.  A functional variant provided further evidence for the association of ARVCF with schizophrenia.

Authors:  Sergi Mas; Miquel Bernardo; Patricia Gassó; Santi Alvarez; Clemente Garcia-Rizo; Miquel Bioque; Brian Kirkpatrick; Amalia Lafuente
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

2.  Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia.

Authors:  Borja García-Bueno; Patricia Gassó; Karina S MacDowell; Luis F Callado; Sergi Mas; Miguel Bernardo; Amalia Lafuente; J Javier Meana; Juan C Leza
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

3.  Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis.

Authors:  Hairong He; Huanhuan Wu; Lihong Yang; Fan Gao; Yajuan Fan; Junqin Feng; Xiancang Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-09       Impact factor: 2.570

4.  Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia.

Authors:  Anna Michalczyk; Justyna Pełka-Wysiecka; Jolanta Kucharska-Mazur; Michał Wroński; Błażej Misiak; Jerzy Samochowiec
Journal:  Ann Gen Psychiatry       Date:  2020-06-17       Impact factor: 3.455

Review 5.  Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Sadia Afsana Mim; Nasrin Sultana; Dinesh Kumar Chellappan; Kamal Dua; Mohammad Amjad Kamal; Rohit Sharma; Talha Bin Emran
Journal:  Oxid Med Cell Longev       Date:  2022-09-21       Impact factor: 7.310

Review 6.  The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis.

Authors:  Thelma Beatriz González-Castro; Yazmín Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Alma Genis-Mendoza; Mariela Alpuin-Reyes
Journal:  Behav Brain Funct       Date:  2016-11-09       Impact factor: 3.759

7.  Evaluation of association of DRD2 TaqIA and -141C InsDel polymorphisms with food intake and anthropometric data in children at the first stages of development.

Authors:  Vanessa Feistauer; Márcia R Vitolo; Paula D B Campagnolo; Vanessa S Mattevi; Silvana Almeida
Journal:  Genet Mol Biol       Date:  2018-07-23       Impact factor: 1.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.